The medical community is buzzing by retatrutide, a new dual GIP and GLP-1 agonist that’s showing significant results in early trials . This treatment works by mimicking natural hormones to regulate appetite and increase feelings of satisfaction , ultimately resulting in substantial body decrease. While currently under review and not broadly avail